On Soriot’s List For AstraZeneca: Building A Decision-Making Culture
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca investors will have to wait two more months to hear details of CEO Pascal Soriot’s plans for re-energizing the struggling big pharma. But the new chief did discuss several near-term objectives for the company and what he has pinpointed as being some of the operational problems, based on discussion with hundreds of employees, during a year-end financial call Jan. 31.
You may also be interested in...
Actavis’ Pulmicort Respules Generics Race Out The Door Before “Short Injunction”
The company is barred from further distributing its budesonide inhalation suspension until April 12; the generic launched April 1 following a patent victory over AstraZeneca, but a New Jersey federal judge said a “limited temporary injunction” was warranted to give the innovator time to seek appellate relief.
Actavis’ Launch Of Pulmicort Respules Generic Halted By Court
One day after declaring one Pulmicort patent invalid and another not infringed, a New Jersey federal judge granted AstraZeneca’s bid to temporarily block Actavis and other ANDA filers from launching and distributing their budesonide generics.
AstraZeneca Faces Uphill Battle In Talking U.S. Docs Into Using Brilinta
U.S. physicians say skepticism over the North American results in the pivotal PLATO study is one of many factors that’s been slowing adoption. Competition with low-cost generics is another.